Prospect: information for the patient

Lenalidomida Mylan 2.5 mg hard capsules EFG

Lenalidomida Mylan 5 mg hard capsules EFG

Lenalidomida Mylan 7.5 mg hard capsules EFG

Lenalidomida Mylan 10 mg hard capsules EFG

Lenalidomida Mylan 15 mg hard capsules EFG

Lenalidomida Mylan 20 mg hard capsules EFG

Lenalidomida Mylan 25 mg hard capsules EFG

lenalidomida

Read this prospect carefully before starting to take this medicine, as it contains important information for you.

• Keep this prospect, as you may need to read it again.
• If you have any doubts, consult your doctor, pharmacist, or nurse.
• This medicine has been prescribed only for you, and you must not give it to other people even if they have the same symptoms as you, as it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.

Lenalidomide Mylan contains the active ingredient “lenalidomide”. This medicine belongs to a group of medicines that affect how the immune system works.

Lenalidomide Mylan is used in adults for:

• Multiple myeloma
• Myleodysplastic syndromes
• Castleman's disease
• Follicular lymphoma

Multiple myeloma

Multiple myeloma is a type of cancer that affects a specific type of white blood cell in the blood, called plasma cells. These cells accumulate in the bone marrow and multiply, becoming uncontrolled. This can damage bones and kidneys.

Multiple myeloma usually does not have a cure. However, the symptoms and signs can be greatly reduced or disappear for a period of time. This is called “remission”.

Multiple myeloma: in patients who have undergone a bone marrow transplant

Lenalidomide Mylan is used as maintenance treatment after recovering adequately from a bone marrow transplant.

Multiple myeloma: in patients who cannot be treated with a bone marrow transplant

Lenalidomide Mylan is taken with other medicines, including:

• A chemotherapy medicine called “bortezomib”;
• An anti-inflammatory called “dexamethasone”;
• A chemotherapy medicine called “melphalan” and
• An immunosuppressant called “prednisone”.

You will take these medicines when starting treatment and then continue taking Lenalidomide Mylan only.

If you are 75 years or older or have moderate to severe kidney problems, your doctor will closely monitor you before starting treatment.

Multiple myeloma: in previously treated patients

Lenalidomide Mylan is taken with an anti-inflammatory called “dexamethasone”.

Lenalidomide Mylan can slow the worsening of multiple myeloma symptoms. It has also been shown to delay the recurrence of multiple myeloma after treatment.

Myleodysplastic syndromes (MDS)

MDS are a group of many different blood and bone marrow diseases. Blood cells become abnormal and do not function correctly. Patients may experience a variety of symptoms, including low red blood cell count (anemia), the need for blood transfusions, and the risk of infection.

Lenalidomide Mylan is used to treat adult patients diagnosed with MDS, when the following points are applicable:

• You need periodic blood transfusions to treat low red blood cell levels (“anemia-dependent transfusions”);
• You have a bone marrow cell anomaly called “isolated 5q deletion cytogenetic anomaly”. This means your body does not produce enough healthy blood cells;
• Other treatments you have used previously are not suitable or do not work well enough.

Lenalidomide Mylan can increase the number of healthy red blood cells produced by the body by reducing the number of abnormal cells:

• This can reduce the number of blood transfusions needed. It may be possible that no transfusions are needed.

Castleman's disease

Castleman's disease is a cancer of a part of the immune system (lymphoid tissue). It affects a type of white blood cell in the blood called “B lymphocytes” or B cells. Castleman's disease is a disease in which B cells grow uncontrollably and accumulate in lymphoid tissue, bone marrow, or blood.

Lenalidomide Mylan is used in monotherapy to treat adult patients who have received previous treatment with other medicines.

Follicular lymphoma (FL)

FL is a slow-growing cancer that affects B lymphocytes. These are a type of white blood cell that helps the body fight infections. When a person has FL, they may store too many of these B lymphocytes in the blood, bone marrow, lymph nodes, and spleen.

Lenalidomide Mylan is used with another medicine called “rituximab” for the treatment of adult patients who have received previous treatment for follicular lymphoma.

How Lenalidomide Mylan works

Lenalidomide Mylan works by affecting the body's immune system and directly attacking cancer. It acts in several ways:

• It stops the development of cancer cells;
• It stops the growth of blood vessels in the cancer;
• It stimulates part of the immune system to attack cancer cells.

You should read the leaflet for all the medicines you are going to take in combination with Lenalidomida Mylan before starting treatment with Lenalidomida Mylan.

Do not take Lenalidomida Mylan

• if you are pregnant, think you may be pregnant or intend to become pregnant, as Lenalidomida Mylan is expected to be harmful to the fetus (see section 2, “Pregnancy, breastfeeding and contraception: information for women and men”);since Lenalidomida Mylan is expected to be harmful to the fetus(see section 2, “Pregnancy, breastfeeding and contraception: information for women and men”);
• if you can become pregnant, unless you follow all the necessary measures to avoid it (see section 2, “Pregnancy, breastfeeding and contraception: information for women and men”). If you can become pregnant, your doctor will note on each prescription that all necessary measures have been taken and will provide you with this confirmation;
• if you are allergic to lenalidomide or to any of the other components of this medicine (including in section 6). If you think you may be allergic, consult your doctor.

If any of these conditions apply to you, do not take Lenalidomida Mylan. In case of doubt, consult your doctor.

Warnings and precautions

Consult your doctor, pharmacist or nurse before starting to take Lenalidomida Mylan if:

• you have ever had blood clots; during treatment, you have a higher risk of presenting blood clots in veins and arteries;
• you have any sign of infection, such as cough or fever;
• you have or have previously had a viral infection, especially hepatitis B infection, varicella zoster or HIV. In case of doubt, consult your doctor. Treatment with Lenalidomida Mylan may make the virus become active again in patients who are carriers of the virus. This leads to the reappearance of the infection. Your doctor must check if you have ever had a hepatitis B infection;
• you have kidney problems; your doctor may adjust your Lenalidomida Mylan dose;
• you have had a heart attack, have ever had a blood clot, or if you smoke, have high blood pressure or high cholesterol levels;
• you have had an allergic reaction while using thalidomide (another medicine used to treat multiple myeloma), such as skin rash, itching, swelling, dizziness or respiratory problems;
• you have experienced in the past a combination of any of the following symptoms: generalised rash, skin redness, high body temperature, flu-like symptoms, elevated liver enzymes, blood abnormalities (eosinophilia), swollen lymph nodes (these are signs of a severe skin reaction called drug reaction with eosinophilia and systemic symptoms, also known as DRESS syndrome or drug hypersensitivity syndrome) (see also section 4 “Possible side effects”).

If any of the above alterations apply to you, inform your doctor, pharmacist or nurse before starting treatment.

At any time, during or after treatment, inform your doctor or nurse immediately if you experience:

• blurred vision, loss of vision or double vision, difficulty speaking, weakness in one arm or leg, a change in the way you walk or balance problems, persistent numbness, decreased sensitivity or loss of sensitivity, memory loss or confusion. All of these can be symptoms of a severe and potentially fatal brain disease called progressive multifocal leukoencephalopathy (PML). If you have any of these symptoms before starting treatment with lenalidomide, inform your doctor if you notice any change in these symptoms.

• shortness of breath, fatigue, dizziness, chest pain, faster heart rate or swelling in the legs or ankles. These can be symptoms of a serious condition called pulmonary hypertension (see section 4).

Analysis and tests

Before starting treatment with Lenalidomida Mylan and during the same, blood tests will be done regularly. This is because Lenalidomida Mylan can cause a decrease in the blood cells that help fight infections (white blood cells) and those that participate in coagulation (platelets).

Your doctor will ask you to have a blood test:

• before treatment;
• every week for the first 8 weeks of treatment;
• subsequently, at least once a month.

You may be evaluated to detect signs of cardiopulmonary problems before and during treatment with lenalidomide.

For patients with SMD who take Lenalidomida Mylan

If you have SMD, you may be more prone to developing a more advanced disease called acute myeloid leukemia (AML). Additionally, it is unknown how lenalidomide affects the likelihood of developing AML. Your doctor may perform tests to detect signs that may better predict the likelihood of developing AML during treatment with Lenalidomida Mylan.

For patients with MCL who take Lenalidomida Mylan

Your doctor will ask you to have a blood test:

• before treatment;
• every week for the first 8 weeks (2 cycles) of treatment;
• subsequently, every 2 weeks in cycles 3 and 4 (see section 3 “Treatment cycle” for more information);
• then at the start of each cycle;
• at least once a month.

For patients with LF who take Lenalidomida Mylan

Your doctor will ask you to have a blood test:

• before treatment;
• every week for the first 3 weeks (1 cycle) of treatment;
• subsequently, every 2 weeks in cycles 2 to 4 (see section 3 “Treatment cycle” for more information).
• then at the start of each cycle and;
• at least once a month.

Your doctor may check if you have a high total tumor burden in the body, including the bone marrow. This could lead to a disease in which the tumors break down and produce unusual levels of chemical substances in the blood that, in turn, can cause kidney failure (this disease is called tumor lysis syndrome).

Your doctor may examine you to check if any changes have occurred in your skin, such as red spots or skin rashes.

Your doctor may adjust your Lenalidomida Mylan dose or interrupt your treatment, depending on the results of your blood tests and your overall condition. If you are a new diagnosis patient, your doctor may also evaluate your treatment based on your age and any other conditions you already have.

Blood donation

You should not donate blood during treatment or for at least 7 days after the end of treatment.

Children and adolescents

The use of Lenalidomida Mylan is not recommended in children and adolescents under 18 years old.

Older adults and people with kidney problems

If you are 75 years old or more or have moderate to severe kidney problems, your doctor will examine you carefully before starting treatment.

Other medicines and Lenalidomida Mylan

Inform your doctor, pharmacist or nurse if you are taking, have recently taken or may need to take any other medicine.

This is because Lenalidomida Mylan may affect how other medicines work. Additionally, some medicines may affect how Lenalidomida Mylan works.

Specifically, inform your doctor or nurse if you are taking any of the following medicines:

• some medicines used to prevent pregnancy, such as oral contraceptives, as they may stop working;
• some medicines used to treat heart problems, such as digoxin;
• some medicines used to thin the blood, such as warfarin.

Pregnancy, breastfeeding and contraception: information for women and men

Pregnancy

Women taking Lenalidomida Mylan

• You should not take Lenalidomida Mylan if you are pregnant, as it is expected to be harmful to the fetus.
• You should not become pregnant while taking Lenalidomida Mylan. Therefore, you must use effective contraceptive methods if there is a possibility that you may become pregnant (see “Contraception”).
• If you become pregnant during treatment with Lenalidomida Mylan, you must stop treatment and inform your doctor immediately.

Men taking Lenalidomida Mylan

• If your partner becomes pregnant while you are taking Lenalidomida Mylan, you must inform your doctor immediately. It is recommended that your partner seek medical advice.
• You should also use effective contraceptive methods (see “Contraception”).

Breastfeeding

You should not breastfeed while taking Lenalidomida Mylan, as it is unknown whether Lenalidomida Mylan passes into breast milk.

Contraception

For women taking Lenalidomida Mylan

Before starting treatment, ask your doctor if you are capable of becoming pregnant, even if you think this is unlikely.

If you can become pregnant:

• you will have pregnancy tests under medical supervision (before each treatment, at least every 4 weeks during treatment and for at least 4 weeks after treatment ends) except that tubal ligation has been confirmed so that eggs do not reach the uterus;

And

• you must use effective contraceptive methods from at least 4 weeks before starting treatment, during treatment and for at least 4 weeks after treatment ends. Your doctor will advise you on the most suitable contraceptive methods.

For men taking Lenalidomida Mylan

Lenalidomida Mylan passes into human semen. If your partner becomes pregnant or may become pregnant and does not use any effective contraceptive method, you must use condoms during treatment and for at least 7 days after treatment ends, even if you have undergone a vasectomy.

Driving and using machines

You should not drive or use machines if you feel dizzy, tired, drowsy, have vertigo or blurred vision after taking Lenalidomida Mylan.

Lenalidomida Mylan contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per capsule: it is essentially “sodium-free”.

Lenalidomide Mylan should be administered by a healthcare professional with experience in the treatment of multiple myeloma, SMD, LCM or LF.

• When Lenalidomide Mylan is used for the treatment of multiple myeloma in patients who cannot be treated with a bone marrow transplant or have undergone other treatments before, it is taken with other medications (see section 1 “What Lenalidomide Mylan is used for”).
• When Lenalidomide Mylan is used for the treatment of multiple myeloma in patients who have received a bone marrow transplant or to treat patients with SMD or LCM, it is taken alone.
• When Lenalidomide Mylan is used for the treatment of follicular lymphoma, it is taken with another medication called “rituximab”.

Follow exactly the administration instructions of Lenalidomide Mylan indicated by your doctor. In case of doubt, consult your doctor or pharmacist.

If you are taking Lenalidomide Mylan with other medications, you should consult the leaflet of those other medications to obtain additional information on their use and effects.

Treatment cycle

Lenalidomide Mylan is taken on certain days during the period of 3 weeks (21 days).

• A “treatment cycle” consists of 21 days.
• Depending on the day of the cycle, you will take one or more medications. However, some days you will not take any medication.
• After completing each cycle of 21 days, you must start a new “cycle” during the following 21 days.

Or

Lenalidomide Mylan is taken on certain days during the period of 4 weeks (28 days).

• A “treatment cycle” consists of 28 days.
• Depending on the day of the cycle, you will take one or more medications. However, some days you will not take any medication.

• After completing each cycle of 28 days, you must start a new “cycle” during the following 28 days.

How much Lenalidomide Mylan to take

Before starting treatment, your doctor will indicate:

• what amount of Lenalidomide Mylan you should take;
• what amount of the other medications you should take with Lenalidomide Mylan, if applicable;
• which days of the treatment cycle you should take each medication.

How and when to take Lenalidomide Mylan

• Swallow the capsules whole, preferably with water.
• Do not break, open or chew the capsules. In the event that the powder from a broken Lenalidomide Mylan capsule comes into contact with the skin, wash the skin immediately and carefully with water and soap.
• Healthcare professionals, caregivers and family members should wear disposable gloves when handling the blister pack or capsule. Subsequently, they should carefully remove the gloves to avoid skin exposure, place them in a plastic polyethylene bag and dispose of them in accordance with local requirements. Then, they should wash their hands thoroughly with water and soap. Pregnant women or those who suspect they may be pregnant should not handle the blister pack or capsule.
• The capsules can be taken with or without food.
• You should take Lenalidomide Mylan approximately at the same time on the scheduled days.

Administration of this medication

To remove the capsule from the blister pack:

• Press only one end of the capsule to allow it to come out through the foil.

• Do not press in the center of the capsule as it may break.

Duration of treatment with Lenalidomide Mylan

Lenalidomide Mylan is taken in treatment cycles, each cycle lasting 21 or 28 days (see “Treatment cycle” above). You should continue the treatment cycles until your doctor informs you to stop treatment.

If you take more Lenalidomide Mylan than you should

If you take more Lenalidomide Mylan than prescribed, inform your doctor immediately.

If you forget to take Lenalidomide Mylan

If you forget to take Lenalidomide Mylan at your usual time and:

• less than 12 hours have passed: take the capsule immediately;
• more than 12 hours have passed: do not take the capsule. Take the next capsule the next day at the usual time.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

Like all medicines, Lenalidomida Mylan can cause side effects, although not everyone will experience them.

If you experience any of the following serious side effects, stop taking Lenalidomida Mylan and seek medical attention immediately, as it may require emergency medical treatment:

• Urticaria, rashes, swelling of the eyes, mouth, or face, difficulty breathing, or itching, which may be symptoms of severe allergic reactions called angioedema and anaphylaxis.
• Severe allergic reaction that may start as a rash in one area but spreads, causing significant skin loss throughout the body (Stevens-Johnson syndrome and/or toxic epidermal necrolysis).
• Generalized rash, high body temperature, increased liver enzymes, blood abnormalities (eosinophilia), swollen lymph nodes, and effects on other body organs (drug reaction with eosinophilia and systemic symptoms, also known as DRESS or drug hypersensitivity syndrome). See section 2.

Consult your doctor immediately if you notice any of the following serious side effects:

• Fever, chills, sore throat, cough, mouth ulcers, or any other symptoms of infection, including sepsis.
• Bleeding (hemorrhage) or hematoma (bruise) not caused by injury.
• Chest pain (thoracic) or leg pain.
• Difficulty breathing.
• Bone pain, muscle pain, confusion, or fatigue that may be due to high levels of calcium in the blood.

Lenalidomida Mylan can reduce the number of white blood cells that fight infections and also the cells in the blood that help to clot (platelets), which can cause bleeding disorders such as nosebleeds and bruises.

Lenalidomida Mylan can also cause blood clots in the veins (thrombosis).

Other side effects

It is essential to note that a reduced number of patients may develop other types of cancer, and this risk may increase with treatment with Lenalidomida Mylan. Therefore, your doctor must carefully evaluate the benefits and risks when prescribing Lenalidomida Mylan.

Very common (may affect more than 1 in 10 people):

• A decrease in the number of red blood cells, which can cause anemia leading to fatigue and weakness.
• Rash, itching.
• Muscle cramps, muscle weakness, muscle pain, muscle discomfort, bone pain, joint pain, back pain, limb pain.
• Generalized swelling, including swelling of the arms and legs.
• Weakness, fatigue.
• Fever and flu-like symptoms, including fever, muscle pain, headache, ear pain, cough, and chills.
• Numbness, tingling, or prickling sensation in the skin, hand or foot pain, dizziness, tremor.
• Loss of appetite, changes in the taste of things.
• Increased pain, tumor size, or redness around the tumor.
• Weight loss.
• Constipation, diarrhea, nausea, vomiting, stomach pain, heartburn.
• Low levels of potassium, calcium, or sodium in the blood.
• Underactive thyroid.
• Chest pain (may be a symptom of pulmonary embolism), difficulty breathing (may be a symptom of pulmonary embolism).
• Infections of all types, including sinusitis, pneumonia, and upper respiratory tract infections.
• Difficulty breathing.
• Blurred vision.
• Cataracts.
• Renal problems, including kidneys that do not function correctly or are unable to maintain normal function.
• Abnormal liver test results.
• High liver test results.
• Changes in a blood protein that can cause swelling of the arteries (vasculitis).
• Increased blood sugar levels (diabetes).
• Decreased blood sugar levels.
• Headache.
• Nosebleeds.
• Dry skin.
• Depression, changes in mood, difficulty sleeping.
• Cough.
• Low blood pressure.
• A vague feeling of discomfort in the body, feeling unwell.
• Inflammatory pain in the mouth, dry mouth.
• Dehydration.

Common (may affect up to 1 in 10 people):

• Red blood cell destruction (hemolytic anemia).
• Certain types of skin tumors.
• Bleeding from the gums, stomach, or intestines.
• Increased blood pressure, slow, fast, or irregular heartbeat.
• Increased levels of a substance released after normal or abnormal destruction of red blood cells.
• Increased levels of a type of protein that indicates inflammation in the body.
• Darkening of the skin; change in skin color due to internal bleeding, usually caused by hematomas; skin inflammation caused by blood accumulation; hematoma.
• Increased uric acid levels in the blood.
• Rashes, redness of the skin, dry skin, peeling or exfoliation of the skin, urticaria.
• Increased sweating, nocturnal sweating.
• Difficulty swallowing, sore throat, difficulty maintaining voice quality or changes in voice.
• Nasal discharge.
• Significant increase or decrease in urine output or inability to control urination.
• Blood in the urine.
• Difficulty breathing, especially when lying down (may be a symptom of heart failure).
• Difficulty achieving an erection.
• Stroke, fainting, vertigo (inner ear disorder causing a sensation of spinning), temporary loss of consciousness.
• Chest pain that radiates to arms, neck, jaw, back, or stomach, sensation of sweating and shortness of breath, nausea or vomiting, which may be symptoms of a heart attack (myocardial infarction).
• Weakness, lack of energy.
• Cervical pain, chest pain.
• Chills.
• Joint swelling.
• Slowed or blocked bile flow from the liver.
• Low levels of phosphate or magnesium in the blood.
• Difficulty speaking.
• Liver damage.
• Balance problems, difficulty moving.
• Deafness, tinnitus (ringing in the ears).
• Nerve pain, abnormal and unpleasant sensation, especially when touched.
• Excess iron in the body.
• Thirst.
• Confusion.
• Dental pain.
• Fall that may cause injury.

Rare (may affect up to 1 in 100 people):

• Brain hemorrhage.
• Circulatory problems.
• Increased blood pressure within the blood vessels that supply the lungs (pulmonary hypertension).
• Loss of vision.
• Loss of libido (sex drive).
• Expulsion of large amounts of urine with bone pain and weakness, which may be symptoms of kidney disease (Fanconi syndrome).
• Yellow pigmentation in the skin, mucous membranes, or eyes (jaundice), pale stools, dark urine, itching skin, rash, abdominal pain or swelling; these may be symptoms of liver damage (hepatic insufficiency).
• Abdominal pain, abdominal swelling, or diarrhea, which may be symptoms of inflammation of the large intestine (colitis or typhlitis).
• Damage to kidney cells (necrotic tubular renal).
• Changes in skin color, sensitivity to sunlight.
• Tumor lysis syndrome – complications may occur during cancer treatment and sometimes even without treatment. These complications occur as a result of the breakdown products of tumor cells that die and may include: changes in blood biochemistry, high levels of potassium, phosphorus, uric acid, and low levels of calcium, which cause changes in kidney function and heart rhythm, seizures, and sometimes death.

Unknown frequency (cannot be estimated from available data):

• Sudden, or mild pain that worsens in the upper stomach and/or back, lasting several days, possibly accompanied by nausea, vomiting, fever, and rapid pulse. These symptoms may be due to pancreatitis.
• Whistling or ringing in the lungs, difficulty breathing, or dry cough, which may be symptoms caused by inflammation of lung tissue.
• Rare cases of muscle degradation (pain, weakness, or swelling) that may lead to kidney problems (rhabdomyolysis), some of which occur when lenalidomida is administered with a statin (a type of medication to reduce cholesterol).
• A skin disease caused by inflammation of small blood vessels, accompanied by joint pain and fever (leucocytoclastic vasculitis).
• Perforation of the stomach or intestine wall. This may lead to a severe infection. Inform your doctor if you have severe stomach pain, fever, nausea, vomiting, blood in the stool, or changes in bowel habits.
• Rejection of solid organ transplants (such as kidney, heart).

Reporting of side effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medication.

• Keep this medication out of the sight and reach of children.
• Do not use this medication after the expiration date that appears on the blister pack and the box after “CAD”/“EXP”. The expiration date is the last day of the month indicated.
• Do not store at a temperature above 30°C.
• Do not use this medication if you observe visible signs of deterioration or signs of improper handling.
• Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.

Composition of Lenalidomida Mylan

Lenalidomida Mylan 2.5 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 2.5 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica, sodium stearate.
• Capsule coating: gelatin, titanium dioxide (E171), yellow iron oxide (E172) and indigo carmine (E132).
• Printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).

Lenalidomida Mylan 5 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 5 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and sodium stearate.
• Capsule coating: titanium dioxide (E171), gelatin.
• Printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).

Lenalidomida Mylan 7.5 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 7.5 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and sodium stearate.
• Capsule coating: yellow iron oxide (E172), titanium dioxide (E171), gelatin.
• Printing ink: shellac, propylene glycol (E1520), black iron oxide (E172) and potassium hydroxide.

Lenalidomida Mylan 10 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 10 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and sodium stearate.
• Capsule coating: gelatin, titanium dioxide (E171), black iron oxide and yellow iron oxide (E172), indigo carmine (E132).
• Printing ink: shellac, propylene glycol (E1520), black iron oxide (E172) and potassium hydroxide.

Lenalidomida Mylan 15 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 15 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and sodium stearate.
• Capsule coating: titanium dioxide (E171), gelatin.
• Printing ink: shellac, propylene glycol (E1520), red iron oxide (E172) and simethicone.

Lenalidomida Mylan 20 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 20 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and sodium stearate.
• Capsule coating: yellow iron oxide (E172), titanium dioxide, indigo carmine (E132), gelatin.
• Printing ink: shellac, propylene glycol (E1520), red iron oxide (E172) and simethicone.

Lenalidomida Mylan 25 mg hard capsules:

• The active substance is lenalidomide. Each capsule contains 25 mg of lenalidomide.
• The other components are:

• Filler of the capsules: pregelatinized maize starch, microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and sodium stearate.
• Capsule coating: titanium dioxide (E171), gelatin.
• Printing ink: shellac, propylene glycol (E1520), potassium hydroxide and black iron oxide (E172).

Appearance of the product and contents of the pack

The hard capsules of Lenalidomida Mylan 2.5 mg are green and white, size 4, 14 mm and marked with “MYLAN/LL 2.5 mg”.

The hard capsules of Lenalidomida Mylan 5 mg are white, size 2, 18 mm and marked with “MYLAN/LL 5 mg”.

The hard capsules of Lenalidomida Mylan 7.5 mg are light grey and white, size 2, 18 mm and marked with “MYLAN/LL 7.5 mg”.

The hard capsules of Lenalidomida Mylan 10 mg are green and light grey, size 0, 22 mm and marked with “MYLAN/LL 10 mg”.

The hard capsules of Lenalidomida Mylan 15 mg are white, size 0, 22 mm and marked with “MYLAN/LL 15 mg”.

The hard capsules of Lenalidomida Mylan 20 mg are green and white, size 0, 22 mm and marked with “MYLAN/LL 20 mg”.

The hard capsules of Lenalidomida Mylan 25 mg are white, size 0, 22 mm and marked with “MYLAN/LL 25 mg”.

The hard capsules Lenalidomida Mylan 2.5 mg, 7.5 mg, 10 mg, 20 mg and 25 mg are supplied in blisters containing 7 hard capsules.

The hard capsules Lenalidomida Mylan 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg are supplied in blisters containing 21 hard capsules and in perforated blisters containing 7 x 1 or 21 x 1 hard capsules.

Only some pack sizes may be marketed.

Marketing authorisation holder

Mylan Ireland Limited

Unit 35/36 Grange Parade,

Baldoyle Industrial Estate

Dublín 13,

Irlanda

Responsible person for manufacturing

McDermott Laboratories Ltd under the commercial name of Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublín 13, Irlanda

Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1

Bad Homburg v. d. Hoehe, Hessen, 61352,

Alemania

Mylan Hungary Kft, Mylan utca 1, 2900 Komárom, Hungría

You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:

Last update of this leaflet: {MM/AAAA}

Other sources of information

The detailed information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu/.